Focus:

Article ID: 717655

Dana-Farber Cancer Institute has been awarded Magnet® status from the American Nurses Credentialing Center (ANCC) for the fourth consecutive time. This prestigious designation recognizes excellence in nursing practice and health care delivery and has been awarded to only 8% percent of hospitals in the United States.

Article ID: 717709

Merkel cell carcinoma (MCC) is a rare, aggressive skin tumor that is diagnosed in approximately 2,000 people each year in the United States. Since MCC affects so few people, it is difficult to study the genetic factors that lead to its development and how those factors correlate with response to therapy. However, Moffitt Cancer Center researchers have developed the largest descriptive genomic analysis of MCC patients to date, in collaboration with Foundation Medicine and the Dana Farber Cancer Institute. Their analysis, published in Clinical Cancer Research, will provide important information to improve the care and treatment of MCC patients for many years to come.

Article ID: 717686

The National Comprehensive Cancer Network® (NCCN®) has begun publishing updated versions of cancer care guidelines adapted for Spanish cancer care providers, in collaboration with the Excellence and Quality in Oncology (ECO) Foundation.

Article ID: 717698

Earlier this month, Nina Shah, MD, joined other myeloma patients, caregivers, and clinical providers on a three-day trek across Iceland’s spectacular landscape.

Article ID: 717676

Today Huntsman Cancer Institute (HCI) at the University of Utah unveiled the Cancer Screening and Education bus. This new, state-of-the-art mobile outreach clinic brings HCI’s clinical and educational expertise and the latest screening technology to residents across Utah, including those who live in distant geographic areas and rural communities.

Article ID: 717657

Lung cancer is the second most common cancer found in both men and women. It is estimated there will be roughly 228,000 new lung cancer cases this year, and nearly 30% of those patients will have mutations in the KRAS pathway. This type of mutation makes the cancer more aggressive and difficult to treat. Researchers at Moffitt Cancer Center are hoping to change that. In a new study published in Cancer Research, the team discovered a new treatment approach that may help this group of patients.

Article ID: 717606

Study in JNCCN—Journal of the National Comprehensive Cancer Network, finds early dose reduction of adjuvant FEC-D chemotherapy negatively impacts overall survival rates for women with intermediate- or high-risk breast cancer.

Article ID: 717447

Patients with metastatic colorectal cancer who engaged in moderate exercise while undergoing chemotherapy tended to have delayed progression of their disease and fewer severe side effects from treatment, according to the results of a new study.

Article ID: 717425

Roswell Park researchers have received recent grant awards totaling more than $15.4 million. These competitive awards include the first National Institutes of Health funding to study a new electronic tobacco device and a state grant supporting Roswell Park's work with the national Cancer Moonshot.

Article ID: 717421

Roswell Park researchers have uncovered a biomarker that may help explain why some patients respond better than others to sorafenib, a chemotherapy commonly prescribed for patients with advanced liver cancer.